Bellevue Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bellevue Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-43,700	Closed	-$1.17M	–	228
2019 Q3	$1.17M	Buy	+43,700	New	+$1.23M	0.02%	139
2019 Q2	–	Sell	-62,300	Closed	-$2.16M	–	218
2019 Q1	$2.16M	Buy	62,300 +36,650	+143%	+$1.06M	0.12%	103
2018 Q4	$501K	Sell	25,650 -1,000	-4%	-$20.6K	0.03%	132
2018 Q3	$710K	Sell	26,650 -14,850	-36%	-$485K	0.05%	132
2018 Q2	$1.57M	Sell	41,500 -1,200	-3%	-$45.9K	0.13%	99
2018 Q1	$1.4M	Sell	42,700 -650	-1%	-$28.5K	0.14%	100
2017 Q4	$2.11M	Buy	43,350 +11,850	+38%	+$599K	0.22%	75
2017 Q3	$1.7M	Sell	31,500 -4,500	-13%	-$264K	0.18%	89
2017 Q2	$2.02M	Hold	36,000	–	–	0.24%	80
2017 Q1	$1.41M	Hold	36,000	–	–	0.19%	89
2016 Q4	$808K	Hold	36,000	–	–	0.17%	95
2016 Q3	$818K	Buy	+36,000	New	+$845K	0.15%	100

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Bellevue Group's PTLA Position: Q4 2019 in Review

Bellevue Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 43,700 shares — an estimated $1.17M sold.

Bellevue Group first reported a position in PTLA in Q3 2016 and held it in 12 quarters. The position peaked at $2.16M in Q1 2019. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

Bellevue Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Bellevue Group sold 43,700 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $1.17M.
Bellevue Group first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 12 quarters.
Bellevue Group's Portola Pharmaceuticals, Inc. position peaked at $2.16M in Q1 2019.
224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.